We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Dr. Ron Newbold is Senior Vice President, US Business Development and Alliances. Ron and his group support Otsuka's efforts to remain a global powerhouse in CNS therapeutics and become a leader in nephrology, by bringing novel and innovative therapeutic solutions into Otsuka's pipeline, from scouting and evaluation to implementation and alliance management.
Ron brings to Otsuka significant experience in external partnering in the Life Sciences field from his previous activities in large Pharma as well as biotech companies. After graduating from the University of Rochester and his postdoctoral fellowship in Medicinal Chemistry at Harvard University he joined Merck, where he was responsible for Strategic Research Initiatives. Following 14 years with Merck, Ron joined Sentigen Biosciences; Celldex Therapeutics; Auspex Pharmaceuticals and most recently Pfizer, where he served as Vice President, Strategic Research Partnerships, prior to joining Otsuka.
This speaker's sessions: